Chinese Journal of Integrative Medicine最新文献

{"title":"Potential Mechanism of Anti-tumor Effect of Trametes robiniophila Murr. (Huaier).","authors":"Ang Li, Lu-Yao Qiu, Tan-Zi Li, Li-Tao Bai, Xiao-Dong Zhao","doi":"10.1007/s11655-025-4147-8","DOIUrl":"10.1007/s11655-025-4147-8","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"650-659"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Euscaphic Acid from Rosa roxburghii Tratt Exerts Anti-colorectal Cancer Activity by Inducing Mitochondrial Apoptosis through ROS/MAPK Pathway.","authors":"Mao-Yu Zhang, Bo-Wen Zhai, Han Huang, Heng Zhao, Yu-Jie Fu","doi":"10.1007/s11655-025-3837-6","DOIUrl":"10.1007/s11655-025-3837-6","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the anti-colorectal cancer (CRC) activity and its potential molecular mechanism of euscaphic acid (EA), a triterpene component from Rosa roxburghii Tratt (RRT), in vitro and in vivo.</p><p><strong>Methods: </strong>EA in RRT was isolated and analyzed for pharmacophore-based virtual screening, and enrichment analysis was performed. HCT116 and CT26 cells were used for in vitro experiments. Meanwhile, we constructed a CT26 syngeneic tumor BALB/c mice model and performed in vivo experiments. Finally, the mitochondrial apoptosis and reactive oxygen species (ROS)/mitogen-activated protein kinase (MAPK) signaling pathway-related proteins were detected by Western blot.</p><p><strong>Results: </strong>EA could inhibit the viability of HCT116 and CT26 cell lines, suppress the biological behaviors including proliferation, migration, and invasion, and induce apoptosis in vitro (P<0.05 or P<0.01). Meanwhile, in vivo experiments showed that EA significantly inhibited the growth of CRC graft tumors (P<0.05 or P<0.01). EA could decrease mitochondrial membrane potential and increase caspase-3/9 activities (P<0.05 or P<0.01). Furthermore, EA promoted the cellular ROS accumulation accompanied by activation of the MAPK signaling pathway, and interestingly, the phosphorylation level of extracellular regulated protein kinases (ERK) was higher (P<0.05 or P<0.01). In addition, the above process could be reversed by the free radical scavenger N-acetylcysteine (P<0.05 or P<0.01).</p><p><strong>Conclusions: </strong>EA could inhibit the growth of CRC cell lines both in vitro and in vivo, and activate the mitochondrial pathway through the ROS/MAPK signaling pathway to induce apoptosis in CRC cell lines. This supports the antitumor potential of triterpene acids from RRT.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"613-622"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intervention of Bazi Bushen Capsule on Benign Prostatic Hyperplasia Concomitant with Erectile Dysfunction Induced by Testosterone Supplementation in Spontaneously Hypertensive Rats.","authors":"Run-Tao Zhang, Yun-Long Hou, Meng-Nan Li, Li-Ping Chang, Xuan Lu, Yu-Ning Jiang, Yong-Jie Meng, Kun-Xu Niu, Si-Wei Wang, Ya-Wen Li, Hong-Rong Li, Cong Wei, Yi-Ling Wu","doi":"10.1007/s11655-025-4220-3","DOIUrl":"10.1007/s11655-025-4220-3","url":null,"abstract":"<p><strong>Objective: </strong>To explore the intrinsic relationship between benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) and evaluate the therapeutic effects of Bazi Bushen Capsule (BZBS).</p><p><strong>Methods: </strong>A model of BPH concomitant with ED was established by using testosterone-supplemented spontaneously hypertensive rats (SHRs). Forty SHRs were divided into 4 groups based on the random number table (n=10 per group), including the model group (SHR+T), the BZBS low-dose group (SHR+T+BZ-low), the BZBS high-dose group (SHR+T+BZ-high), and the finasteride group (SHR+T+Fi). Ten Wistar-Kyoto rats were set up as the control group. Except for the control group, SHRs were subcutaneously injected with 3 mg/kg testosterone, and treated with different therapeutic modalities at the same time for 28 days. The androgen signaling markers related to the prostate, markers of cell proliferation and apoptosis, indicators of corpus cavernosum fibrosis and contraction/relaxation function, inflammatory markers in the prostate and corpus cavernosum tissue were assessed. Network pharmacology analysis was conducted to identify the key therapeutic targets of BZBS and to further validate the experimental findings.</p><p><strong>Results: </strong>BZBS significantly reduced prostate wet weight and prostate index, and improved pathological changes (P<0.01). BZBS modulated expressions of proliferating cell nuclear antigen, Bcl-2-associated X protein, and B-cell lymphoma 2 expression (P<0.05 or P<0.01). BZBS alleviated corpus cavernosum fibrosis, increased the smooth muscle area, upregulated α-smooth muscle actin expression, and improved functional markers-including Ras homolog family member A, Rho-associated coiled-coil containing protein kinase 2, endothelial nitric oxide synthase, nitric oxide, and cyclic guanosine monophosphate (P<0.05 or P<0.01). BZBS also regulated androgen levels, including dihydrotestosterone, 5α-reductase type II, and prostate-specific antigen (P<0.05 or P<0.01). Notably, BZBS effectively attenuated inflammatory responses in both the prostate and corpus cavernosum tissue (P<0.05 or P<0.01). Unlike finasteride-which primarily reduces prostate inflammation-BZBS exhibited a dual therapeutic effect on both BPH and ED. Network pharmacology further suggested that BZBS exerts its effects through multiple inflammation-related targets and pathways.</p><p><strong>Conclusions: </strong>Chronic inflammation plays a crucial role in both BPH and ED. BZBS effectively ameliorates these conditions by modulating inflammatory processes.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"631-641"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Yinhua Miyanling Tablets for Uncomplicated Urinary Tract Infections: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Non-inferiority Clinical Trial.","authors":"Zhen Du, Yi-Wen Tang, Lu-Dong Qiao, Liang Cui, Hui-Ling Wu, Jin-Qiang Yang, Feng Liu, Zhuo Yin, Jian Zhang, Tie-Jun Pan, Shan Chen, Zhan Gao","doi":"10.1007/s11655-026-4154-4","DOIUrl":"10.1007/s11655-026-4154-4","url":null,"abstract":"<p><strong>Objective: </strong>To compare the efficacy and safety of Yinhua Miyanling Tablets (YMT) versus levofloxacin in the treatment of female patients with uncomplicated urinary tract infections (uUTIs).</p><p><strong>Methods: </strong>A multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical trial was conducted from August 2022 to August 2023 in 9 tertiary hospitals across China. By using a block randomization method, 480 female patients with uUTI were randomized in a 1:1 ratio to receive either YMT 2 g, 4 times daily for 7 consecutive days (plus levofloxacin-matching placebo) or levofloxacin tablets 0.5 g, once daily for 3 consecutive days (plus YMT-matching placebo). The primary outcome was the proportion of patients requiring additional antimicrobial therapy for uUTIs between day 1 and days 38-42 of treatment, while the secondary outcomes included the Acute Cystitis Symptom Score (ACSS) and urinalysis after 42-d treatment. Safety assessments were conducted based on all adverse events (AEs) and abnormal laboratory test results.</p><p><strong>Results: </strong>A total of 458 women with uUTIs were enrolled in the modified intention-to-treat analysis. Between day 1 and days 38-42 of treatment, the proportion of patients requiring additional antimicrobial therapy was 20.8% (47/226) in the YMT group and 9.9% (23/232) in the levofloxacin group (P<0.01). The non-inferiority criterion (margin 8 = 20%) was met. YMT treatment improved ACSS typical symptoms and quality-of-life scores and urinalysis results compared with levofloxacin, although the differences between groups were not statistically significant (P>0.05). The incidence of treatment-emergent AEs was 7.7% (17/226) in the YMT group and 7.0% (16/232) in the levofloxacin group (P=0.775).</p><p><strong>Conclusions: </strong>YMT is non-inferior to levofloxacin in the proportion of patients requiring additional antimicrobial therapy during treatment of uUTIs in women. YMT treatment is as effective as levofloxacin in terms of improving uUTI symptoms and quality-of-life scores. YMT may be used as a promising adjunctive therapy for uUTIs in women. (Trial registration No. ChiCTR2200066312).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"588-595"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Biqi Capsules in 2,267 Patients with Rheumatoid Arthritis: A Real-World Clinical Study.","authors":"Xie-Li Ma, Cong-Min Xia, Tian Chang, Zi-Xia Liu, Yu-Chen Yang, Chuan-Hui Yao, Wei-Xiang Liu, Xun Gong, Quan Jiang","doi":"10.1007/s11655-026-4137-5","DOIUrl":"10.1007/s11655-026-4137-5","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effectiveness and safety of Biqi Capsules in the treatment of rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>This multicenter, prospective cohort study was conducted across more than 100 centers in China. Data on RA patients were collected from the CERTAIN database between January 2019 and March 2024. Patients were categorized into an exposed group and a control group. The control group was treated with conventional Western medicine, and the exposed group was combined with Biqi Capsules (0.3 g/capsule, 4 capsules per dose, orally, 2-3 times/d) on the basis of conventional treatment. Propensity score matching (PSM) was applied to balance baseline characteristics. The main outcomes was the Disease Activity Score-28 (DAS28-ESR), and secondary outcomes included Health Assessment Questionnaire (HAQ), Visual Analogue Scale (VAS) for pain, tender joint count (TJC), swollen joint count (SJC), Patient Global Assessment (PGA), and Evaluator Global Assessment (EGA) scores, as well as erythrocyte sedimentation rate (ESR), and other laboratory test results as safety indicators.</p><p><strong>Results: </strong>A total of 2,267 patient records were analyzed, with 711 in the exposed group and 1,556 in the control group. After PSM, 710 patients were included in each group, with comparable baseline demographic characteristics (P>0.05). Following matching, pre-treatment HAQ and TJC were similar between groups (P>0.05), while significant differences were observed in DAS28-ESR, EGA, PGA, VAS, SJC, TJC, and ESR (P<0.01). Post-treatment analysis showed that all indices improved significantly in both groups (P<0.01). Furthermore, post-treatment levels of EGA, PGA, VAS, SJC, and TJC were statistically significant between the two groups (P<0.01). The reduction in DAS28-ESR was significantly greater in the exposed group than in the control group (P<0.01). Statistically greater improvements were also found in EGA, PGA, SJC, TJC, and ESR, indicating superior clinical improvement in the exposed group (P<0.01). The incidence of abnormal γ-glutamyl transferase and creatinine levels were higher in the control group than in the exposed group (P<0.01 or P<0.05), while no significant differences were observed in other safety indicators between the two groups (P>0.05).</p><p><strong>Conclusion: </strong>Biqi Capsules combined with conventional treatment of Western medicine effectively reduce RA disease activity, lower inflammation levels, relieve clinical symptoms, and do not increase the incidence of adverse events. (Registration No. NCT05219214).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"596-602"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145984474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Acupuncture in Postoperative Recovery for Gastrointestinal Tumors: A Systematic Review and Meta-Analysis.","authors":"Si-Si Ren, Yu-Chao Hou, Shan-Ya Qin, Shu-Qun Cheng","doi":"10.1007/s11655-025-4149-6","DOIUrl":"10.1007/s11655-025-4149-6","url":null,"abstract":"<p><strong>Background: </strong>Postoperative gastrointestinal dysfunction (POGD) is a common complication following gastrointestinal tumor surgery, significantly impairing patient recovery and quality of life. The efficacy of acupuncture in improving POGD remains unclear.</p><p><strong>Objective: </strong>To evaluate the role of acupuncture in enhancing postoperative gastrointestinal function in patients with gastrointestinal tumors, providing evidence-based clinical insights.</p><p><strong>Methods: </strong>Relevant studies were searched in PubMed, Cochrane Library, EMbase, Web of Science, China National Knowledge Infrastructure, Wanfang Data, and VIP Database from inception to December 4, 2024. Only clinical-type studies involving acupuncture or electroacupuncture in the treatment of patients with gastrointestinal tumors were included. The primary outcomes were the first flatus time, first bowel movement time, first oral feeding, and hospitalization time. Secondary outcomes included white blood cell (WBC) count and C-reactive protein (CRP) level. Study quality was appraised using the domain-based evaluation described in the Cochrane Handbook.</p><p><strong>Results: </strong>This study included 8 randomized control trials (CRCTs) involving 413 patients. Meta-analysis revealed that acupuncture significantly reduced the time to first flatus (P<0.05), time to first oral feeding (P<0.05), and hospital stay (P<0.05). However, it did not significantly affect the time to first bowel movement (P=0.53). Additionally, acupuncture significantly decreased CRP levels at 3 and 6/7 d postoperatively (P<0.05), as well as WBC counts at 6/7 d (P<0.05). The overall risk of bias of the included studies was rated as low to unclear.</p><p><strong>Conclusions: </strong>Current evidence supports acupuncture as an effective adjunctive treatment for improving postoperative POGD in patients with gastrointestinal tumors. Further, high-quality RCTs are needed to validate these findings and optimize clinical protocols. (Registration No. CRD420250651195).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"642-649"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms of Yiguanjian Decoction against Thyroid Cancer: A Network-Based Pharmacological Investigation.","authors":"Rui-Min Liang, Fa-Huan Song, Xin-Yue Deng, Shu-Ting Xu, Ling-Hui Wang, Ya-Wen Guo, Lei Zhu","doi":"10.1007/s11655-026-4156-2","DOIUrl":"https://doi.org/10.1007/s11655-026-4156-2","url":null,"abstract":"<p><strong>Objective: </strong>To identify the active components of Yiguanjian Decoction (YGJ) and elucidate their molecular actions against thyroid cancer.</p><p><strong>Methods: </strong>The TCMSP, TCMID, and BATMAN-TCM databases were used to screen the bioactive components in YGJ and their therapeutic targets. Subsequently, thyroid cancer-related targets were compiled from Drugbank, DisGeNET, and OMIM. Protein-protein interaction (PPI) networks were generated from the STRING database, and functional enrichment analyses (GO/KEGG) were conducted via Metascape and DAVID. Molecular docking simulations were performed to evaluate binding affinities between key compounds and targets. Finally, in vitro and in vivo experiments were carried out to validate YGJ's anti-cancer effects, including suppression of thyroid cancer cell proliferation and migration and induction of apoptosis.</p><p><strong>Results: </strong>The systematic screening identified 69 bioactive compounds in YGJ and 358 corresponding therapeutic targets. Cytoscape's Network Analyzer revealed 10 hub targets (AKT1, FOS, JUN, MAPK1, MAPK14, MAPK3, MYC, RELA, SRC, and TP53) with top centrality scores in the PPI network. Functional enrichment analyses revealed that YGJ's anti-thyroid cancer activity involved 3 major pathways, including MAPK, Toll-like receptor, and T cell receptor signaling (all P<0.001). In vitro experiments demonstrated that YGJ effectively inhibited 8505C and TPC-1 cell proliferation and migration by downregulating key oncogenic regulators (p-ERK, NF-κB, c-MYC). In vivo xenograft studies further confirmed that YGJ significantly reduced tumor volume and weight in BALB/c mice, suppressed Ki67 expression, and showed no obvious toxicity to major organs. Molecular docking further identified essential hydrogen bonding and hydrophobic interactions for stabilizing ligand-target complexes.</p><p><strong>Conclusions: </strong>This study comprehensively reveals YGJ's pharmacological properties against thyroid cancer, identifying its core targets and multi-pathway mechanisms.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-target Mechanisms of Natural Compounds in Inhibiting Colitis-Associated Carcinogenesis: Implications for Novel Therapeutic Strategies.","authors":"Yi-Fan Liu, Cheng-Zhi Wang, Zong-Yue Gao, Zuo-Wu Xi","doi":"10.1007/s11655-026-4165-1","DOIUrl":"https://doi.org/10.1007/s11655-026-4165-1","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148263579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xuefu Zhuyu Decoction Reduces Excessive Collagen Deposition and Crosslinking in Myocardial Fibrosis via CTR1-Copper-LOX Axis.","authors":"Ya-Fen Wang, Shi-Jun Yue, Jia-Yao Li, Si-Tong Meng, Min Zheng, Yu-Fang Zhang, Ying Gu, Bin Hou, Ya-Ning Biao","doi":"10.1007/s11655-026-4042-y","DOIUrl":"https://doi.org/10.1007/s11655-026-4042-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To explore the molecular mechanism of Xuefu Zhuyu Decoction (XFZYD) against myocardial fibrosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The active components of XFZYD were identified by high performance liquid chromatography (HPLC). Network pharmacology, molecular docking, and affinity dot-mass spectrometry (AD-MS) were used to predict and validate the binding interaction between XFZYD components and copper transporter 1 (CTR1). Sixty male Kunming mice were randomly divided into 6 groups using a random number table. Control, isoproterenol hydrochloride (ISO), captopril, low-, medium-, and high-dose XFZYD (5.69, 11.38, and 22.76 g/kg) groups, with 10 mice in each group. Except the control group, mice received daily subcutaneous injection of ISO (10 mg/kg) for 28 d to induce myocardial fibrosis, concurrently treated with respective drugs by gavage. Cardiac function was assessed by echocardiography (ECG) and electrocardiography (UCG). Serum myocardial injury markers and transforming growth factor beta 1 (TGF-β 1) were measured by a biochemical analyzer and enzyme-linked Immunosorbent assay (ELISA). Pathological changes and collagen deposition was observed using HE, Masson and sirius red staining methods. Copper content in cardiac tissue was determined by inductively coupled plasma mass spectrometry (ICP-MS), and protein expressions of collagen I, III, alpha-smooth muscle actin (α-SMA), lysyl oxidase (LOX), CTR1, copper chaperone for superoxide dismutase (CCS), and cytochrome c oxidase 17 (COX17) were detected by Western blot, immunohistochemistry, and immunofluorescence. In vitro, TGF-β 1 (5 ng/mL)-stimulated NIH-3T3 fibroblasts were treated with XFZYD (60 mg/L), with or without CuCl&lt;sub&gt;2&lt;/sub&gt; (20 µ mol/L) or SLC31A1 overexpression for 24 h, and the same indicators were evaluated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;HPLC identified 7 major components in XFZYD. Network pharmacology revealed that XFZYD targets copper metabolism related genes. Molecular docking showed strong binding affinities between the 7 compounds and CTR1, and AD-MS confirmed direct binding of paeoniflorin and amygdalin to CTR1. In vivo, XFZYD could ameliorate the collagen deposition, cardiac dysfunction, and elevated levels of collagen I/III, α-SMA, LOX, and copper content exhibited in ISO-induced myocardial fibrosis mice (P&lt;0.05 or P&lt;0.01). In vitro, XFZYD had the effects of suppressing copper overload and the upregulation of LOX, collagen I/III, and α-SMA in TGF β 1 stimulated NIH-3T3 fibroblasts, whereas co-treatment with CuCl&lt;sub&gt;2&lt;/sub&gt; exacerbates these fibrotic responses and attenuates the protective effect of XFZYD (P&lt;0.05 or P&lt;0.01). XFZYD had the effect of partially reversing the enhanced copper accumulation, LOX activation, and collagen deposition induced by SLC31A1 (CTR1) overexpression in TGF β 1 stimulated fibroblasts, and SLC31A1 overexpression reduces its efficacy (P&lt;0.05 or P&lt;0.01).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;XFZYD exerted a protecti","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Chinese Herbal Medicine and Active Ingredients on Diabetic Cardiomyopathy: Focus on Pyroptosis.","authors":"Chang Fu, Ying Zhang, Sai-Song Chai, Jian-Xun Ren","doi":"10.1007/s11655-026-4040-0","DOIUrl":"https://doi.org/10.1007/s11655-026-4040-0","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}